News from promedior A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 13, 2020, 10:44 ET Promedior Announces Completion of Acquisition by Roche

Promedior, Inc. today announced the successful completion of its previously announced sale to Roche (SIX: RO, ROG; OTCQX: RHHBY). With this...

Nov 15, 2019, 07:30 ET Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior....

Jun 17, 2019, 15:30 ET Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, announced positive safety and...

May 20, 2019, 11:30 ET Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that positive...

Mar 26, 2019, 08:00 ET Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a...